Proton International London: The therapeutic challenge in paediatric oncology

Cancers in infants, children, teenagers and young adults present distinct therapeutic challenges. Treatment decisions must con­sider not only tumour control, but also the impact of therapy on growth, neurocogni­tive development, endocrine function and long-term survivorship.

Radiotherapy remains a key component of treatment for many paediatric malig­nancies. However, developing tissues are particularly sensitive to radiation injury, and late effects may manifest months or years after therapy. These may include neurocognitive impairment, growth dis­turbance, endocrine dysfunction, cardio­pulmonary toxicity and secondary malig­nancies. Minimising unnecessary radiation exposure is therefore central to modern paediatric radiotherapy practice.

The dosimetric rationale for proton beam therapy
Proton beam therapy (PBT) offers a dis­tinct physical advantage over conven­tional photon radiotherapy. Through the Bragg peak phenomenon, protons deposit the majority of their energy at a defined depth, with minimal exit dose beyond the target volume.

This enables highly conformal dose dis­tribution and a reduction in integral dose to surrounding normal tissues. In paediat­ric patients, where long-term survivorship is a central consideration, reducing dose to developing organs and limiting low-dose exposure may help mitigate both acute toxicity and late effects.

By sparing healthy tissue beyond the tu­mour, proton therapy aims to balance ef­fective tumour treatment with protection of critical structures that are essential for a child’s ongoing development and future quality of life.

Paediatric tumour types commonly considered for proton therapy
Proton therapy is most frequently con­sidered for localised tumours, particularly those situated adjacent to critical struc­tures. Indications commonly include:

• Central nervous system tumours (me­dulloblastoma, ependymoma, glioma, ATRT, craniopharyngioma, germ cell tumours)
• Sarcomas (rhabdomyosarcoma, Ewing’s sarcoma, osteosarcoma, chordoma, chondrosarcoma)
• Neuroblastoma
• Wilms tumour
• Spinal cord tumours
• Hodgkin and non-Hodgkin lymphoma
• Head and neck malignancies
• Ocular tumours such as retinoblastoma

Tumours of the brain, spinal cord and head and neck are particularly strong can­didates due to the opportunity to reduce dose to organs at risk, including the co­chlea, optic pathways, hypothalamic–pitu­itary axis, heart and lungs.

Supporting referrals from the Middle East
Proton International London proudly sup­ports paediatric referrals from across the Gulf
region and wider Middle East. We recognise that overseas treatment requires structured coordination between referring oncologists, sponsoring authorities and families.

Our consultant-led team provides timely case review and defined treatment plan­ning timelines, alongside comprehensive clinical documentation to support spon­sor approval processes. Direct clinician-to-clinician communication is prioritised throughout the pathway.

A dedicated international patient team assists families with visa documentation, Arabic interpreter services, accommoda­tion coordination and practical logistics during their stay in London.

Our focus is seamless integration with the child’s primary oncology team, ensur­ing continuity of care before, during and after treatment.

A consultant-led multidisciplinary model
Delivered in partnership with University College London Hospitals NHS Founda­tion Trust (UCLH), Proton International London provides private proton beam therapy within a leading academic hospi­tal environment.

All paediatric referrals are reviewed within a multidisciplinary framework to ensure appropriate patient selection and alignment with the child’s overall treat­ment strategy.